Life Sciences Archive » March, 2023

Life Sciences - March, 2023

345 articles

• J&J Can't Keep Talc Ch. 11 During High Court Appeal
• 7th Circ. Kicks Back Illustration Infringement Case, Again
• Roundup Buyer Attys Get $5.75M In Fees In False Ad Case
• Doctor's Patent App Survives PTAB's 2nd Derivation Ruling
• Surescripts Holds Monopoly In E-Prescriptions, Judge Says
• AmerisourceBergen Seeks Toss Of DOJ's Opioid Suit
• 4 Potential Paths For High Court In Amgen Patent Case
• Fed. Circ. Upholds ITC Ban On Philip Morris IQOS Devices
• Don't Miss It: Latham, Crone Law Lead Week's Hot Deals
• Biotech Firms Pursue Alternatives While IPOs Remain Cold
• Jury Says Sandoz Owes $39M For Eyelash Drug Infringement
• Ky. Gov. Signs Bill To Legalize Medical Cannabis
• SEC Keeps Heat On Cos. Seeking To Bar Investor Proposals
• NJ Man Wants No Jail Time In Pandion Insider Trading Case
• Patent Suit Over Generic IBS Drugs Will Go On
• Surgeon Loses Bid For Tripled Damages In Patent Case
• EU Official Questions Criticism Of EU, US Enforcers Talking
• Ex-CEO Whistleblower Nets $12M In Hospital's $69M FCA Deal
• Pesticide Maker Backs Monsanto In 11th Circ. Roundup Redo
• Manufacturer Skirts Death Claims Over Stuck Car Seat Buckle
• Fox Ex-Producer Case Is A Lesson In Joint Representation
• Cannabis Cos. Must Heed Growing Federal Investigatory Risks
• Chemical Cos. Want To Keep 2 Asbestos Suits Separate
• Hearing Loss Biotech Escapes Investors' Stock Suit
• SG Sides With Teva In High Court Skinny Label Patent Case
• ITC Confronts Divergent Views On Expanding COVID IP Deal
• Outcome's Problems Came From 'Fraud Island,' Jury Hears
• 11th Circ. Tosses Fla. Attorney's Mask Mandate Suit
• Biogen Judge Tosses Investor Suit, Calling It 'House Of Cards'
• Chancery Flat-Lines Bid To Stop Heart Valve Co. Patent Sale
• Biotech Co. Codiak Plans Ch. 11 Sale Of Lab, IP Assets
• 3rd Circ. Orders Trial In Pharma Fraud Coverage Suit
• McKesson Beats Oncology Kickback Whistleblower Suit
• Delaware High Court Skeptical Of State's Monsanto PCB Suit
• Walmart Can't Nix 'Maximum Strength' Lidocaine False Ad Suit
• Ex-Compliance Chief Who Aided Feds In Oxy Case Avoids Jail
• A Tale Of 2 State Tax Sourcing Decisions: The Pa. Court's Path
• Illumina Investor Loses Insider Trading Appeal In 2nd Circ.
• 6th Circ. Widens FCA Split, Curtails Kickback Law's Scope
• FTC Calls Juul-Altria Settlement Offer 'Woefully Short'
• Whistleblower Grafting Old Claim On New Suit, Skin Co. Says
• Biz Groups Ask High Court To Use 'Objective' FCA Standard
• Allergan Drops Willfulness Allegation In Eyelash Drug Suit
• 'Fake It Till You Make It' Was The Outcome Way, Jury Hears
• Apple Can Call CEO For Rebuttal In Trade Secrets Trial
• Heart Device Maker Tells Del. Court: Patents Already Sold
• 2nd Circ. Backs Toss Of FCA Case Involving Cancer Group
• Justices Question Post-Dobbs Bar On Georgia Abortion Law
• Recent Growth Factors Driving Life Sciences Transactions
• A Tale Of 2 State Tax Sourcing Decisions: The Va. Court's Path
• Insights After High Court Arguments In Amgen Patent Case
• Vanda Can See FDA Docs On Drug Label Denial, Judge Says
• Stanford Law Protest Highlights Rise Of Incivility In Discourse
• 50 Cent Settles False Advertising Suit With Fla. Medical Spa
• Holland & Knight Adds K&L Gates Tech Policy Team In DC
• DOJ Fights Pharma Exec's Bid To Delay Price-Fixing Trial
• Outcome Ex-Growth Chief Says He Didn't 'Corrupt' Workers
• Novartis Co. 'Jumped The Gun' With Eyelash Drug, Jury Told
• 7th Circ. Revives Ill. Student's Pandemic Tuition Refund Suit
• Texas Attys. Can't Lead Class In Abortion Row, Judge Told
• Court Eyes Attorney Actions In 'Sham' Androgel Patent Suit
• Justices Experiment With Enablement Paths In Amgen IP Row
• Kansas Supreme Court Skeptical Of Laws Restricting Abortion
• How Kickbacks Became King In False Claims Act Litigation
• Ohio AG Says Pharmacy Middlemen Colluded To Hike Prices
• Milwaukee Industry Park's Ex-Owner Liable For Cleanup
• Wholesaler To Pay $33.4M In Abbott Labs Test Strips TM Row
• Cardiac Implant Maker Sued In Del. Over Snubbed Offer
• $490M FCA Award Unconstitutional, Distributor Insists
• Psychedelics Policy Roundup: RI Sens. Pitch Psilocybin Bill
• Sorrento Therapeutics Agrees To Shareholder Committee
• Consumers Contest Abbott's Bid To Toss Infant Formula MDL
• No Emotional Damages For Loss Of Pets, Mich. Panel Rules
• Dispute Prevention Strategies To Halt Strife Before It Starts
• Catching Up With Delaware's Chancery Court
• Dormant Commerce Clause Issues Are Evolving In Cannabis
• Federal Judge Downs 'Rapid Release' Tylenol Suit
• Biotech Firm Codiak BioSciences Hits Ch. 11 With Sale Plan
• Opioid Theory Reaches 'Alcohol, Guns, Phones,' 4th Circ. Told
• Amgen Supreme Court Arguments Aren't Just About Biology
• Drugmaker Not Defamed By Medical Journal, 3rd Circ. Rules
• Bystolic 'Side Deals' Deemed Legit, Not Generic Delay Plans
• Monster's $167M Additional Relief Bid 'Falls Short,' VPX Says
• NH High Court Nixes Med. Monitoring In PFAS Class Action
• Minn. Attorney General Discusses Juul, First E-Cigarette Trial
• CR Bard Defeats Counterclaims In $27M Surgical IP Row
• Tricida Heading For Ch. 11 Confirmation Fight With Creditors
• NYPD Can't Dodge Suit Over Expansive DNA Database
• Icahn Calls Illumina's Grail Move 'A New Low' Amid Proxy War
• Ex-Dialysis Co. Execs Can't Dodge SEC Accounting Fraud Suit
• BetterHelp Hit Again With Class Action Over Data Protection
• UK Litigation Roundup: Here's What You Missed In London
• Health Hires: Gordon & Rees, Axogen, Capstan
• Attys Get $18.8M In Allergan, Merz 'Pay-For-Delay' Settlement
• Denial Of Xtandi March-In Rights Petition Appealed To HHS
• 5th Circ. Halts FDA Ban On RJ Reynolds Menthol Vapes
• Boston Scientific Says University 'Poisoned' $42M Patent Trial
• FTC Blasts Illumina's 'Conspiracy Theory' Over Grail Deal
• IP Forecast: BMW Looks To Toss Patent Suit, Seeks Sanctions
• Medical Software Co. Sued After 2nd Data Breach In 4 Years
• Would-Be Ark. Pot Seller Loses Suit Over Licensing Process
• What To Know Before Justices Take On Patent Enablement
• Masimo Unveils Board Changes Amid Politan Suit In Delaware
• Gerber Wants Class Decertified In Formula False Ad Suit
• Defamation Alternatives For Suing Hoax Social Media Users
• Practical Skills Young Attorneys Must Master To Be Happier
• Ex-Aegerion Rep Can't Nix Fraud Counts Over Edit, Feds Say
• Deals Rumor Mill: Commanders, FTX, Baxter International
• New Mich. Cannabis Policy May Lower Costs For Some Cos.
• Wyoming Judge Blocks State's Abortion Ban, For Now
• Aquavit Scores $10M Win In Aquagold TM Fight Against Rivals
• Feds Tell 6th Circ. Pharmacies Have Opioid Duties
• No Dispute Gilead HIV Drug Causes Injuries, Patients Say
• Spain Touts Highest Female Inventors Rate, US Trails Behind
• Chancery Won't Redo AmerisourceBergen Opioid Suit
• Sanofi Tells Justices It Couldn't Give Away EpiPen Rival
• Moderna Exec Stands By COVID-19 Vaccine Price Increase
• Amarin Asks Fed. Circ. To Undo Heart Drug IP Decision
• McDermott Lands Deals Attys From Pillsbury, Gibson Dunn
• J&J Plans High Court Appeal After 3rd Circ. Tosses Talc Ch. 11
• Could The Supreme Court Legalize Marijuana Federally?
• DC Circ. Backs Dismissal Of Navy Worker's Vax Mandate Suit
• Rite Aid Hit With Investor Suit Over DOJ Opioid Action
• Okla. Justices OK Abortions That Preserve Women's Lives
• NIH Won't Seize Patents To Cut Price Of Cancer Drug Xtandi
• High Court Urged To Back Objective FCA Knowledge Standard
• Freezer Co. Says Supplier Must Chip In On $15M Embryo Loss
• AbbVie Inks $2.7M Deal To End Humira FCA Kickback Battle
• DOJ Vowed 'Difficult Cases.' It Still Bowed To UnitedHealth
• Okla. Cancels First Pot License Over 'Ghost Ownership'
• Amgen Must Face Regeneron's Bundling Antitrust Suit
• Treasury Clarifies Eligibility For Chips Tax Credit
• GW Pharma Investors Ink $7.75M Deal In Suit Over Jazz Sale
• Citadel Securities, Others Want Biotech Spoofing Suit Nixed
• FTC Warns Of Harm In Generic Parkinson's Drug Antitrust Suit
• Stimwave Secures Ch. 11 Plan Confirmation In Delaware
• Glancy Prongay Drops Out Of Blood Drug Lead Counsel Race
• 3rd Circ. Skeptical Vaccine Refusal A 'Fundamental Right'
• Pennsylvania Is Gathering Momentum On Adult-Use Cannabis
• Fed. Circ. Urged To Upend Actavis' $12M Legal Fee Deduction
• Cannabis REIT Hit With Shareholder Derivative Action
• NantCell Kicked Off Creditor Committee In Sorrento Ch. 11
• Colorado Biopharma Co. Settles Stock Split, Share Award Suit
• DOJ Quietly Abandons UnitedHealth Merger Appeal
• Idaho Hospital To Stop Delivering Babies Amid Legal Dilemma
• FDA Urges Court To Keep Abortion Drug Regulations Intact
• High Court Tosses Immunity Ruling In Missouri Abortion Fight
• Justices Let Gov't Join FCA Scienter Args, Balk At Extra Time
• HHS Advisory Opinion Serves As Free Drug Program Guide
• DOJ Defends Ask For Docs From Drug Price-Fixing MDL
• Illumina Says Icahn Nominees Would 'Damage' Core Business
• 50 Years In, Industry Has Knives Out For Potent Kickback Law
• Sorrento Shareholders Say They Need Committee In Ch. 11
• Feds Want $490M Award After FCA Kickback Verdict
• Holmes Restitution Hearing Draws Autograph-Seekers
• Court Backs $125M Sorrento Cancer Drug Arbitration Win
• Startup Targets 'Purged' Emails In Suit Against Apple
• Olly Wants Excess Melatonin Suit Trimmed
• SVB's Fall Portends Even Leaner Times For Private Startups
• Ex-Biotech Exec Ordered To Pay $45K Over Fraud Allegations
• FTC Urges DC Circ. Not To Prolong Endo-Impax Monopoly
• Bipartisan Reps. Introduce Bills To Regulate CBD Products
• ABA Opinion Should Help Clarify Which Ethics Rules Apply
• Merck, Viatris Settle Diabetes Drug Patent Fight After Appeal
• Balwani Snags Last-Minute Prison Reprieve With Fresh Appeal
• ND Supreme Court Finds Abortion Ban Likely Unconstitutional
• DOJ Asks USPTO To Look At Anti-Competitive Patent Abuse
• Surescripts, FTC 'Ought To Be Talking Again,' Judge Says
• Cell Research Co. Strikes Deal To End Clinical Data Suit
• Curtailing Offshore Tax-Advantaged Investment In China
• 6th Circ. Pans 'Shocking Lack Of Evidence' In Med Mal Suit
• J&J Ordered To Pay $40M In Damages In Antitrust Suit
• Monsanto Asks 11th Circ. To Bar Doctor's Roundup Claims
• NJ Panel Says Suit Isn't Coherent Enough To Fully Dismiss
• J&J And Ethicon Score Pelvic Mesh Trial Win In Fla.
• 4 Ways To Reboot Your Firm's Stalled Diversity Program
• Families In GSK MDL Rip Shook Hardy For 'Ironic' Costs Bid
• Texas Judge Challenges Claim Abortion Pill Suit Filed Too Late
• SEC Axes Eli Lilly Bid To Duck Diversity, Abortion Reports
• Pharma Co. Gets Investor Suit Over New Diazepam Drug Axed
• Why Holmes Is Unlikely To Avoid Prison While She Appeals
• Driver Says Pharmacy, Courier Co. Don't Pay Minimum Wage
• Bank Failures Shine Light On Corporate Governance Risks
• Biz Court Ignored Deception In Fraud Suit, NC Justices Hear
• Icahn Says Illumina Stance 'Insulting' As Proxy War Brews
• Judge Refuses To Split Upcoming Zetia Antitrust Trial
• DOJ's Google Sanctions Motion Shows Risks Of Auto-Deletion
• Janssen Says Whistleblower FCA Claim Already Disclosed
• J&J MDL Atty Joins Barnes & Thornburg's Windy City Office
• PE-Backed Biz Interrupts $425M Merger Of Biotech Firms
• Amgen Hid IRS' $10B Tax Dispute, Shareholder Suit Alleges
• Calbiotech Urges Rejection Of Ex-Worker's Sanctions Bid
• Roche Blasts Attys' 'Misconduct' In Diabetes Fraud Deposition
• Ohio's GOP Justices Vote To Review Block On Abortion Ban
• Pharma Co. Says Rival Stole Psychedelic Treatment Formula
• Fed. Circ. Unsure Vanda's Sleep Med Hetlioz Is Patentable
• CVS Tells 9th Circ. Choctaw's Claims Must Be Arbitrated
• Mich. Seeks Murder Verdict Over Moldy Drugs After Feds Fail
• Mylan Execs Were Unaware Of W.Va. Plant Issues, Court Told
• To Fight Consumer Hair Loss Claims, Focus On Causation
• What To Expect From A Litigation Finance Industry Recession
• OKYO Pharma Eyes Raising $5.74M From Share Placing
• Apollo Funds Taking Univar Solutions Private In $8.1B Deal
• CVS Can't Escape FCA Suit Alleging Drugmaker Collusion
• Pharma Cos. Say Civil Evidence Off Limits In Criminal Case
• Surescripts Says Loyalty Programs' End Moots FTC Case
• How Public Companies Are Responding To SVB's Collapse
• J&J Wants Rival's 'Meritless Delay Tactic' Denied
• Fintiv Challenge Rolls On, But Odds Of Sinking Rule Dwindle
• Allergan Gets FCA Suit Tossed On Remand From 9th Circ.
• Feds Say Rite Aid Ignored 'Red Flags' On Opioid Prescriptions
• Texas Sees 1st Suit Alleging Aborted Fetus' Wrongful Death
• Judge Goes Public With Abortion Hearing Info After Outcry
• Recent Trends In Multiple First Generic Drug Filings
• Pierre Fabre Benzene Shampoo Suit Not A Wash, Court Told
• 2nd Circ. Won't Undo Colgate's $300M Loss In ERISA Suit
• Law Groups Tell Full 11th Circ. Roundup Claims Negate EPA
• 3rd Circ. Grants Amicus Bids Of Profs, Ex-Judge In LTL Case
• 2 Firms Lead Sanofi's Provention Bio Buy Worth $2.9B
• Illumina Hit With Proxy Contest By Activist Investor Carl Icahn
• J&J Unit Ch. 11 Case Shows Texas 2-Step May Be Wrong Move
• Fed. Circ. Revives Tech Giants' Suit Targeting Fintiv
• Pfizer Buys Seagen In $43B Enterprise Value Deal
• Altria Fights Telling Jury About Juul Settling Vaping Claims
• Judge Not Convinced By DOJ's 'Say-So' In Vax IP Row
• Calif. Appeal Panel Affirms Ax Of Zantac Prop 65 Claims
• Ethicon And J&J Snag 4th Circ. Win In Pelvic Mesh Appeal
• HPV Suit Not Covered By Geico Auto Policy, Judge Says
• CORRECTED: 'A Huge Waste Of Time': Judge Gives Allen & Overy Atty Earful
• Lawmakers Urge Transparency In Federal Pot Reevaluation
• FCA Knowledge Element: NY Already Got It Right
• Generic Drug Buyers Get $75M In Price-Fixing Deals Approved
• UK Litigation Roundup: Here's What You Missed In London
• Breaking Down Maryland's Adult-Use Cannabis Bill
• Janssen Must Hand Over Records In Kickback Case
• Taxation With Representation: Gibson Dunn, Wachtell, Davis
• UK Teva Ruling Brings Patent Remedy Into Question
• Family Sues Fla. Airbnb Over Baby's Fentanyl Death
• Foreign Tech Bill Hones Commerce's Growing Nat. Sec. Role
• Mylan Asks Supreme Court To Deny Sanofi's EpiPen Bid
• Stimwave Pays $10M To Avoid Prosecution; Ex-CEO Charged
• Family Sues Over ICE Detainee's COVID-19 Death
• CBD Co. Can't Avoid Counterclaims In Trademark Dispute
• FDA Calls For Better Baby Formula Safety Practices
• Cannabis And Psychedelics Roundup: Sens. Eye More Studies
• Teva Wants Out of Case Targeting Blockbuster MS Drug
• HHS Budget Highlights Insulin Costs, Family Planning
• FDA Seeks $7.2B In 2024 Budget, Highlighting Food Safety
• Altria To FTC: There's No More Juul Investment To Challenge
• Gas Facility Opponents Say FERC Didn't Weigh Health Impacts
• House Panel Focuses On Expanding JOBS Act Benefits
• Regeneron Ignoring FCA Law 'Common Sense,' Feds Say
• Mintz Debuts 'Femtech' Practice For Life Science Clients
• Moderna Tries To Kick Ex-Judge Out Of COVID Vax IP Row
• AmEx Could Face Shareholder Vote On Abortion Ban Risks
• Anti-Abortion Group To Take Free Speech Fight To High Court
• Illumina Says EU Comms Underscore FTC Bias Over Grail
• Judge Says Ipsen IP Row Belongs In Belgium
• Opioid Judge Eyes New Bellwethers Amid 'Unwieldy' Delays
• Gilead Wins $131M From Fla. Clinics Over HIV Meds Scam
• Zetia Buyers Face Tough Road For Bid To Split Up Trial
• DC Judge Axes Medical Device Group's Copyright Office Suit
• FDA Proposes New Tobacco, E-Cig Manufacturing Rule
• 3 Firms Face Off For Lead Counsel Spot In Blood Drug Suit
• Ex-CEO Convicted In Landmark Opioid Case Gets 27 Months
• Solenis To Buy Diversey In $4.6B PE-Backed, Go-Private Deal
• 'Clear Quid Pro Quo': HHS Jeers Big Pharma's Kickback Salvo
• Talc Claimants Rip J&J Unit's Bid For Full 3rd Circ. Rehearing
• Amgen Says Sanofi Contradicting Itself In High Court IP Feud
• Women Denied Abortions In Medical Emergencies Sue Texas
• DEA's Proposed Telehealth Rules May Be Too Restrictive
• Ohio Nurse Says Hospital Failed To Pay Required OT Wages
• CVS Beats NY AG Drug Subsidy Tying Suit, For Now
• Walgreens Seeks Quick Exit in Kids' Cough Medicine Suit
• Hedge Fund Manager Priest Denied Rehearing From 1st Circ.
• Cozen O'Connor Launches Data Privacy Practice In Chicago
• 10th Circ. Ruling Shows Hemp Issues Need Congressional Fix
• DOJ Cautions Execs With Novel Insider Trading Case
• 9th Circ. Doubts FTC's Industry Ban For COVID PPE Delays
• Merck Hit With 3rd-Party Payor Suit Over Vaccine Bundling
• Fed. Circ. Squints To Find Wrinkle Treatment Differences
• Pharma Co. Wants Suit Over Underpaying Board Chair Axed
• ITC Judge Details Why Cannabis Cos. Beat IP Investigation
• $54M Wolverine, 3M PFAS Settlement Nears Final Approval
• Gilead Prevails In Antiviral IP Claim Fight At Fed. Circ.
• Retired Judge, Profs Oppose J&J Unit's Chapter 11 Bid
• Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues
• DuPont Hit With Pension Benefit Miscalculation Suit
• Tribes And Others Fight To Keep McKinsey Opioid Suit Alive
• Justices Leave Questions Open On Dual-Purpose Atty Advice
• Michigan's New Abortion Rights May Crush Old Legal Barriers
• Nixon Peabody Expands Complex Disputes Practice In NY
• COVID Test Co. Will Pay $500K To End SEC Fraud Claims
• Justices Won't Hear Ex-Abbott Worker's Race Bias Appeal
• Elizabeth Holmes Fights 'Sweeping' $900M Restitution Bid
• Ex-Judges Worried About Where COVID Vax IP Row Will Go
• Hain Gets Midtrial Win On Claim Baby Food Caused Autism
• 11th Circ. Agrees Ala. Pharmacist's COVID Suit Is State Matter
• MacroGenics Beats Cancer Drug Securities Suit At 4th Circ.
• Precigen Strikes $13M Deal In Investors' Gas Fraud Suit
• Investors' COVID Vax Suit Against Drugmaker Tossed
• Gov't Doesn't Owe Cotter Indemnity For Radiation Injury Suit
• Amgen, Teva Want Another Shot At Quick Sensipar Appeal
• An Update On The Eliminating Kickbacks In Recovery Act
• HEC Says Axed Novartis Patent Win 'Not Remotely Certworthy'
• Nurses And Doctor Face Fines Over False COVID-19 Claims
• Co-Counsel Named In L'Oreal Hair Relaxer MDL
• Health Hires: McDermott, Gordon Rees
• Trending At The PTAB: Fintiv Is Alive, But With Way Less Zip
• Life Sciences Group Of The Year: Covington
• UK Litigation Roundup: Here's What You Missed In London
• Cannabis And Psychedelics Roundup: A Caucus Reintroduced
• J&J Page-Limit Flub Stifles Amgen Injunction, For Now
• Fertility Clinic 'Doomed' Baby To Stomach Removal, Suit Says
• Catalyst Launches Patent Suits Over Drug Firdapse
• IP Forecast: Atty's TM Fraud Fight Makes Its Way To Fed. Circ.
• Worry Over Abortion Info Access Spurs Call For Net Neutrality
• CBD Pharma Co. Sues Beverage Co. Over $25M Sale Deal
• FCA Enforcement And Litigation Trends To Watch
• Antitrust Suit Against Amarin Pharma Forges Ahead
• Ex-Pharmacy Tech's FMLA Firing Suit Heads To Trial
• Eli Lilly Says 'Vitriol' Behind Teva's Bid To Triple IP Verdict
• Butzel Long Adds Veteran Gov't Relations Atty In DC
• Judge Criticized By Medical Device Co. Tosses Its Retrial Bid
• Members In $8M Class Action Got Bad Deal, 11th Circ. Told
• Feds Want 15 Years For Former CEO In Landmark Opioid Case
• Bill Would Close Patent 'Loophole' Used To Block Generics
• Absent Federal Action, Tribal Cannabis Laws Remain In Limbo
• Life Sciences Group Of The Year: Arnold & Porter
• Deals Rumor Mill: Pfizer, Altria, Stripe
• As Opioid Sellers Win Vital Verdict, Families See Silver Lining
• Biogen Owes Patent Royalties For MS Drug, Genentech Says
• Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now
• Judge Trims Retailer's TM Suit Over Celebrity Laser Treatment
• Calif. Co. Files Patent Suits Over Pot Extraction Technologies
• Some Zetia Buyers No Longer Want Split Trial
• Michigan Cases To Watch In 2023
• Garland Defends DOJ Steps On Justices' Safety, Major Probes
• Patients Sue Med Group Over Delayed Response To Hack
• DOJ Fraud Section's 2022 By The Numbers
• Class Cert. Denied Again In Gout Drug Antitrust Case
• J&J Ch. 11 Dismissal Ignores Mass Tort Bankruptcy Principles
• Distributors Win Milestone Trial Over Individual Opioid Abuse
• ITC 100-Day Early Disposition: Little Used But Top Of Mind
• Life Sciences Group Of The Year: Quinn Emanuel